Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About Mitchell MCN
  • Careers
  • MCNTalk
  • Contact Us

Mitchell MCN

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About Mitchell MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / The Shkreli Problem

February 3, 2016

The Shkreli Problem

by Jen Jenkins

Martin Shkreli dominated headlines last year as the villain of the pharmaceutical industry. We blogged on MCNTalk about the drug Daraprim, which his company, Turing Pharmaceuticals, purchased, subsequently raising the price per pill from $13.50 to $750. The Internet immediately labeled him the “Most Hated Man in America,” but despite all the criticism, Mr. Shkreli forged ahead and even defended his actions by saying, “I could have raised it higher and made more profits for our shareholders. Which is my primary duty. Again, no one wants to say it. No one’s proud of it. But this is a capitalist society, capitalist system and capitalist rules. My investors expect me to maximize profits.” Comments such as these are a very small glimpse into the reason why big pharma’s problem with price hikes can be called “the Shkreli problem.”

It has become commonplace for drug companies to raise the prices of old drugs by any percentage that they please. Although the percentage of these price bumps may not be as exaggerated as what Shkreli did with Daraprim, it still raises the question: why should they be able to raise prices of old drugs with no justification? This Forbes article shares some of Martin Shkreli’s background and discusses how he went from simply talking about inventing new drugs to dramatically raising the prices of existing ones, as well as some of his other disreputable deeds in between. One of the biggest differences between Shkreli’s acts and those of other pharmaceutical companies is the publicity. Everyone else avoids the press when exercising price hikes while Shkreli unabashedly promotes and defends what he is doing. Respectable drug companies have, for the most part, distanced themselves from this ludicrous display of behavior. Although they essentially all follow the same practices, they want it to be clear that their reasoning surely does not align with that of Shkreli.

The fact is, 80% of drugs in the United States are generic, thus our current system highly encourages drug companies to either focus on making money off of drugs that serve a smaller population of people or raise the prices on existing drugs. Another problematic side effect of this is that new drugs, research, and innovation are falling by the wayside. Martin Shkreli’s behavior is an exaggerated, albeit disturbing outlook on big pharma and decisions that are being made largely out of the public eye.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Tagged: Cost Containment, Health Policy Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

15 + eight =

Primary Sidebar

Recent Posts

  • February Clinic Calendars Are Available
  • Mitchell MCN’s Client Portal Login Page is Changing
  • IRO Team to Host Webinar about Genetics on Dec. 5, 2019
  • December Clinic Calendars are Now Available
  • Mitchell MCN’s IRO Team to Host CEU in December

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About Mitchell MCN
  • Careers

Division Headquarters

Mitchell MCN
1301 5th Ave., Ste. 2900
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2021 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.